ArticleMolecular biomedicine2026
Lipid nanoparticle-mediated transcription factor EB mRNA delivery for the treatment of metabolic dysfunction-associated steatotic liver disease.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent disorder characterized by excessive hepatic lipid accumulation, frequently progressing to steatohepatitis, fibrosis, and cirrhosis. Transcription factor EB (TFEB) coordinates lysosomal biogenesis, autophagy, and lipid catabolism, and therefore represents a potential therapeutic target; however, safe and direct strategies for selectively enhancing hepatic TFEB activity remain limited. Here, liver-targeted lipid nanoparticles (LNPs) were developed to deliver mRNAs encoding wild-type TFEB or the constitutively active TFEB S211A mutant, and their efficacy was evaluated in cellular and choline-deficient, L-amino acid-defined high-fat diet (CDAHFD)-induced mouse models of MASLD. LNP-mediated delivery increased hepatic TFEB expression, enhanced autophagic flux, and reprogrammed metabolic pathways toward fatty acid oxidation (e.g., CPT1A and ACOX1) while suppressing the expression of lipogenic genes (e.g., FASN, ACC, and SREBP1). Consequently, targeted TFEB mRNA therapy significantly reduced hepatic triglyceride content, attenuated steatosis, lowered MASLD activity scores, and decreased fibrotic remodeling. Mechanistically, transcriptomic profiling, ChIP-qPCR, promoter-reporter assays, and targeted knockdown models indicated that TFEB exerts its protective effects against lipid accumulation at least partly by transcriptionally activating the fibroblast growth factor 21 (FGF21) signaling pathway. Collectively, these findings establish LNP-mediated TFEB mRNA delivery as a useful preclinical approach for investigating hepatic biology and provide a targeted, transient, and non-integrating genetic strategy with potential for the treatment of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.